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New approaches to treat Alzheimer Disease 
A few months ago, a promising study about Alzheimer Disease (AD), a type of dementia, 
was published in JACC (Journal of the American College of Cardiology). Dementia 
affects around 50 million people worldwide and around 60-70% of them suffer AD. It is 
estimated that in 2050 there will be more than 115 million people diagnosed (WHO, 
2019).  
Dementia is a disease that damages cognitive capacity interfering in daily activities. AD 
is a progressive dementia that worsens through time and lasts around 10-12 years, when 
the patient dies due to infections or other organic failure. This decline on cognitive 
function can start at early ages, around 50-60 years, or later, although it is not yet 
established the cause that triggers the disease because it is a multifactorial 
neurodegenerative disease. Around 10% of cases it is a hereditary transmission due to 
mutations in specific chromosomes which would ease the deposition of amyloid burden 
and, thus, cause neurotoxicity. Furthermore, there are other risk factors to consider, such 
as high blood pressure for a long period of time, brain injury, high homocysteine levels 
(molecule that might be involved in chronic diseases such as cardiopathy, depression 
and possibly AD), medical history of dementia or Down syndrome and low vitamin B12. 
It is also important to have an active brain training during life to avoid this kind of 
diseases. 
AD is characterised by Β-amyloid accumulation which is established in senile plaques 
and begins some events that contribute to cellular death, lipid oxidation, cellular 
membrane disruption which leads to an inflammatory response, causing 
neuroinflammation and cerebral atrophy due to neuron loss. Neurofibrillary tangles, 
which are aggregates of tau protein, also contribute to these processes and, eventually, 
to cognitive impairment.  
This kind of dementia is also characterised by diminish synaptic density, neuron loss and 
neuronal degeneration in hippocampus. Neuron loss can lead to a lack of 
neurotransmitters that will cause the main symptomatology of AD. It is also included a 
blood-brain barrier disruption, allowing plasmatic protein loss and provoking cerebral 
blood flow changes and an increase in thrombin and platelet activation, enhancing fibrine 
clot formation. Hence, there is a vascular involvement in AD, as once described Alois 
Alzheimer, who identified for the first time the disease symptoms in 1906.  
On the first stage, there is a minor symptomatology, the patient has full autonomy and 
only complex tasks can be a handicap. As the disease progresses, the patient requires 
more attention until he is completely dependent on an assistant. It affects memory, 
language comprehension and execution, performance of intentional movements and 
spatial perception. 
No cure has been found to treat this disease. However, the aim in therapeutics is to 
lessen the progress, control behaviour issues and support family members and 
assistants. Some vitamins have been related with cognitive function maintenance, 
including vitamin B12, B6, E and folic acid, in early phases. Moreover, antioxidants or 
phytomedicines such as Ginkgo biloba, might contribute on improving the symptoms, 
although they are not enough as an individual therapy.  It is also available a kind of drugs, 
acetylcholinesterase inhibitors, that help keeping a neurotransmitter (acetylcholine) that 
lacks in this disease, improving behaviour, apathy, functional capacity, deliria and 
memory. These are donepezil, rivastigmine and galantamine, which have some common 
adverse effects: gastrointestinal discomfort, loss of hunger and cardiac rhythm disorders. 
There is also other drug used in moderate-severe cases called memantine, which is an 
uncompetitive NMDA-receptor antagonist and avoids neuronal overstimulation caused 
by glutamate and, this way, avoids neurotoxicity as well. However, these drugs might 
lessen the symptoms during a relative short period of time but not stop AD’s progression  
As there is no effective treatment to cure or at least delay AD’s progression scientists 
decided to take a turn and try to avoid senile plaques and clots by improving blood 
circulation. Therefore, coagulation was the target of the experiment carried out by CNIC 
(Centro Nacional de Investigaciones Cardiovasculares Carlos III), as they considered 
that, by improving blood circulation through the brain and avoiding clot formation by 
anticoagulant use, the disease would be less aggressive. Nevertheless, there are some 
limitations in anticoagulant use, which are constant monitorization and bleeding risk and 
this is the reason why the tested drug was dabigatran, due to the lower haemorrhagic 
frequency.  
Dabigatran, the drug used in this experiment, is a direct prothrombin inhibitor used in 
stroke prevention in patients with a particular arrythmia with one or more risk factors 
(previous stroke or ischemic transitory accident, diabetes mellitus, older than 75 years, 
cardiac insufficiency, arterial hypertension) and venous thromboembolism prevention in 
post-surgical patients. Seldom are there interactions between dabigatran and other 
drugs, which is an advantage regarding other anticoagulants, and, in the same way, 
there is lower intracranial bleeding risk. There is an antidote called idarucizumab in case 
of life-threatening haemorrhages. Several precautions must be considered, since there 
is a haemorrhagic risk. It is not recommended in patients who have hypersensitivity, 
kidney failure, hepatic illness, active haemorrhages (ulcers, recent intracranial bleeding, 
oesophageal varices or vascular aneurysm), concomitant anticoagulant treatment or 
other drugs that can interact. In any case, this is one of the anticoagulants with less risk 
of bleeding.  
The experiment was designed with transgenic mice who suffered AD and non-
transgenic, who did not suffer the disease. Each type of mice was divided in two groups 
so that one of each would be fed with dabigatran etexilate, which metabolises to 
dabigatran inside the body, and the other with placebo. When mice were 8 weeks old, 
before β-amyloid deposition, blood samples were analysed in all groups. The diluted 
thrombin time showed a delayed clot formation in treated mice plasm, and it was slightly 
higher in the ones that did not have de disease. During the treatment, cerebral blood flow 
was checked, and spatial memory was tested, the first one by magnetic resonance 
imaging and the other one by using Barnes maze. There was a significative reduction on 
the time mice spent to find the exit in the group with AD who was fed with dabigatran. 
Mice who was fed with placebo didn’t remember where the exit was. Therefore, this drug 
is beneficial in memory retention. Additionally, a lower blood perfusion in the brain was 
detected in non-treated mice, 15% less than the healthy ones. This was prevented in 
mice treated with dabigatran, so it also maintains a better cerebral blood flow.  
Mice were sacrificed at week 30 and 60, when brain tissue was examined with different 
tests. Insoluble fibrine was quantified in cortex and hippocampus in both cases and 
differences were sought between the treated and non-treated group. Fibrine deposition 
increased as the mouse grew old and AD progressed. After a long-term treatment with 
dabigatran there was not as many fibrine in the brain as in the placebo group’s brain. 
The amyloid plaques grew between week 30 and 60, but in the treated group it grew 
about 24% less compared to placebo group. Moreover, the most toxic oligomeric β-
amylase, diminished about 50% if they were treated with dabigatran. Likewise, 
anticoagulation reduced neuroinflammatory activity around 30% in 60-week mice, since 
decreased lymphocyte T recruitment inside the brain. AD also has an abnormal 
hypertrophic effect in cells around capillary which is neutralised by dabigatran so that 
blood-brain barrier can keep its integrity and avoiding fibrin extravasation. Additionally, 
dabigatran prevents aquaporin distribution, which participates in B-amylase uptake, 
elimination and active transport. 
Summarizing, β-amylase strongly interacts with fibrin and fibrinogen (responsible for 
coagulation) and induces clot formation resistant to degradation. Long-term 
anticoagulant decreases amyloid plaques and B-amylase oligomer levels avoiding clots. 
Dabigatran effect was stronger in a long-term intake since AD is chronic and fibrin 
accumulation increases with time. Not only did dabigatran allow better B-amylase 
elimination through blood-brain barrier, than it also diminished deposition in cortical 
vessels that cause cerebral angiopathy and improved blood flow. Thus, memory and 
cognitive function improved and neuroinflammation decreased. Concluding, dabigatran 
can delay AD symptoms if it is early treated. 
Despite all those beneficial effects, some limitations should be considered. For instance, 
there is a greater incidence of intracellular haemorrhage in AD patients and amyloid 
cerebral angiopathy. This vasculopathies are related with worse cognitive activity and 
the use of this antithrombotic agent has been discussed among this group of people. 
Nevertheless, dabigatran has a low bleeding risk and it did not cause any haemorrhage 
during the study and it also has an antidote in case of serious bleeding. However, more 
trials are required to extrapolate long-term therapy in humans, but this drug is already on 
sale, so transition might be faster. It also would be interesting to study whether it would 
be useful in an already established disease. Furthermore, as AD is a multifactorial 
disease, there should be a combined therapy according to each individual.  
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